Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

3.14.145.94
dgid:
enl:
npi:0
-Advertisement-
-Advertisement-
Journal Scan
Oncology

Role of CAR-T Cells in Mediating Pancreatic Ductal Adenocarcinoma Remission

Posted on

Although pancreatic ductal adenocarcinoma (PDAC) is an orphan disease with a low incidence, PDAC’s high mortality rate makes it the fourth leading cause of cancer-related deaths. An international group of researchers hopes a new immunotherapy involving “switchable” CAR-T cells could eventually improve survival or cure patients with advanced PDAC. The switchable CAR-T cells bind to a peptide grafted onto an antibody that allows them to be activated or deactivated. The team harvested immune cells from PDAC patients and used them to cultivate conventional and switchable HER2-targeting CAR-T cells. Mice engrafted with human PDAC cells were injected with either type of CAR-T cell or inactive switches. Five months later, only the mice given CAR-T cells were tumor free. Being able to switch CAR-T cells off should improve safety by reducing off-target effects.

Read more here.

Reference

Raj D, Yang MH, Rodgers D, et al. Switchable CAR-T cells mediate remission in metastatic pancreatic ductal adenocarcinoma. Gut. 2018 Aug 18. pii: gutjnl-2018-316595. doi: 10.1136/gutjnl-2018-316595.

-Advertisement-
Related Articles
Liver Cancer Rates Increase in Developed Countries
May 18, 2020
Rare Disease Day: Get to Know About Sarcoma
Mar 27, 2020
ASCO Cancels Annual Meeting, Switches to Virtual Format
Mar 25, 2020
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-